Date：26 July (Wednesday)
Time：12:20 – 13:50 (GMT+8)
General Manager, Eli Lilly and Company (Taiwan) Inc.
Hide Katsuma is the General Manager of Eli Lilly Taiwan since May 2021, leading the commercial operations and accountable for Diabetes, Oncology and Bio Medicines’ portfolio of products.
Katsuma received a bachelor's degree in commerce from Kansai University in 1998 and a master's degree in business administration from Duke University in 2008.
Katsuma joined Lilly Japan in 2008 and had taken several sales and marketing roles such as sales representative, pre-launch marketing, as well as the customer engagement project lead at Lilly USA. Katsuma was named a brand director in Neuroscience in 2014, and led brand management in Alzheimer and Pain, and then appointed as Senior Director of Human Resources in 2017 to oversee the human resources strategy and operations for 3000+ employees at Lilly Japan. In 2018, Katsuma was assigned as Senior Director of Oncology Business Unit, overseeing the commercial strategies and operations in oncology business in Japan. Katsuma had been a member of Eli Lilly Japan Executive Committee from 2017 to 2021 and also had served Diversity Equity & Inclusion Champion for Lilly Japan for 2 years.
As General Manager of Lilly Taiwan, Katsuma sits on the North Asia-Pacific (NAPAC) Hub’s Leadership Team. Starting Jan 2023, Katsuma also serves President of IRPMA (International Research-Based Pharmaceutical Manufacturers Association) which consists of 40+ pharmaceutical manufacturers from Europe, Japan, and the U.S. with a presence in Taiwan.